Monoclonal antibody cancer therapies

Eisenstein, T. (ed.). 2003. Hepatitis B, the Virus, the Disease and the Vaccine. Kluwer. Grossbard, M. 1998. Monoclonal Antibody Based Therapy of Cancer. Dekker. 

Funaro A, Florenstein AL, Santoro P, et al. Monoclonal antibodies and therapy of human cancers. Biotechnology Advances 18 385-401 (2000). 

Saleh MN, LoBuglio AF, Trail PA, In Monoclonal Antibody-Based Therapy of Cancer (Ed. Grossband M), pp. 397 16. Marcel Dekker, New York, 1998. 

Kasprzyk, P. G., S. U. Song, P. P. Di Fiore, and C. R. King. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res, 52 2771-2776.1992. 

The first therapeutic antibody approved (Orthoclone OKT-3 or Muromonab CD3, 1986) was indicated not for cancer treatment, but for controlling acute rejection of transplanted organs (kidney, heart, and liver). Nowadays, other clinical indications such as asthma, rheumatoid arthritis, psoriasis, and Crohn s disease are treated with mAbs (see Chapter 17) (Antibody Engineering and Manufacture, 2005 Monoclonal Antibodies and Therapies, 2004 Hot Drugs, 2004 Walsh, 2004). 

Biotechnology-derived products may be classified into monoclonal antibodies, gene therapy, vaccines, enzymes, and interleukins. The current major therapeutic areas for these substances are cancer or cancer-related conditions, AIDS or HIV-related disease, diabetes, human growth hormone, myocardial infarction, and inflammatory disease. 

Cancer cells express a variety of antigens that are attractive targets for monoclonal antibody-based therapy (Table 51-3). Several monoclonal antibodies are FDA-approved for treating lymphoid and... 

Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature implications for therapy with monoclonal antibodies. Cancer Cells 1991 3 77-85. 

Targeted Cancer Therapy. Table 2 Main differences between monoclonal antibodies and small-molecule tyrosine kinase inhibitors... 

Colloidal gold-labeled (strept)avidin can be used as highly sensitive detection reagents for microscopy techniques (Cubie and Norval, 1989) (Chapter 24). Finally, cytotoxic substances coupled to (strept)avidin can be used to direct cell-killing activity toward a tumor-cell-bound, biotinylated monoclonal antibody (or other targeting molecule) for cancer therapy (Hashimoto et al, 1984) (Chapter 21). 

Reisfeld, R.A., Yang, H.M., Mullet B., Wargalla, U.C., Schrappe, M., and Wrasidlo, W. (1989) Promises, problems, and prospects of monoclonal antibody-drug conjugates for cancer therapy. Antibody, Immunoconjugates, Radiopharm. 2, 217-224. 

Oldham, R.K. (1983). Monoclonal antibodies in cancer therapy. J. Clin. Oncol. 1 582-590. 

Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy, Drug Development Research 61 172-187 (2004). 

Adams GP, Weiner LM. Monoclonal antibody therapy of cancer, Nature Biotechnology 23 1147-1157 (2005). 

---